Lindis Blood Care announces successful financing for its tumour-cell-removal medical device
A novel approach designed to be a safe and cost-effective way to reliably remove tumor cells from autologous blood
Lindis blood Care, a company aiming to set new standards for blood management during cancer surgeries with its medical device CATUVAB®, announced the successful first closing of a follow-on financing round. The new investment will be used to prepare for the anticipated approval of the medical device (CE Mark) and product launch in Europe. The FDA process for marketing approval in the US is ongoing. The round was led by Brandenburg Kapital, the venture-capital arm of the investment bank of the State of Brandenburg. High-Tech Gründerfonds, existing and new private investors as well as the founders, Dr. Franzpeter Bracht and Dr. Horst Lindhofer, participated in the financing round.
“We are grateful for the continued support of our existing shareholders and welcome our new investors who share our vision of introducing the first medical device that has the potential to redefine the protocols of intraoperative blood salvage in cancer surgeries,” commented Dr. Franzpeter Bracht, founder and Managing Director of Lindis Blood Care. “The results of our clinical certification study REMOVE were outstanding; confirmed the excellent safety profile and met all clinical endpoints with high statistical significance. We are now focusing our efforts on concluding the processes to receive CE Mark in Europe and FDA marketing approval in the US as well as preparing for market launch.”
CATUVAB® is a novel approach designed to be a safe and cost-effective way to reliably remove tumor cells from autologous blood during high blood loss surgeries. Its mechanism of action is physical and does not involve pharmacological, immunological, or metabolic action. The approach can easily be integrated into existing clinical practice and represents a cost-effective method compared to fully burdened allogeneic blood transfusions and the treatment-related costs due to severe side effects associated with such transfusions.
“We are excited to support Lindis Blood Care in their mission to revolutionize oncological surgery with CATUVAB®. Their innovation has the potential to significantly enhance patient safety and outcomes by enabling safe autologous blood transfusions during cancer surgeries. Our investment reflects our strong belief in the clinical and market potential of CATUVAB® and the dedicated team driving its development. We are proud to be part of this journey, helping to bring a transformative solution to patients and healthcare providers” emphasized Dr. Moritz Beissenhirtz, Investment Director Life Sciences at Brandenburg Kapital.
Results from a confirmatory open-label, multicenter clinical study (REMOVE), that enrolled more than 130 patients to assess CATUVAB® for use during intraoperative blood salvage (IBS) procedures in cancer surgeries, showed that CATUVAB® was safe and effective, meeting all primary and secondary endpoints with high statistical significance. The top-line data were presented during the NATA24 Annual Symposium in Bologna on April 19, 2024.
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.
Most read news
More news from our other portals
Something is happening in the life science industry ...
This is what true pioneering spirit looks like: Plenty of innovative start-ups are bringing fresh ideas, lifeblood and entrepreneurial spirit to change tomorrow's world for the better. Immerse yourself in the world of these young companies and take the opportunity to get in touch with the founders.
